Delving into the Latest Updates on PLH-2301 with Synapse

Overview

Basic Info

Drug Type

Unknown

Synonyms

PLH-2301

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Active Organization

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This is a Phase 2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of PLH-2301 in subjects with sarcopenia.
Eligible subjects aged 65 years and older will be randomized to receive placebo or one of three dose levels of PLH-2301 once daily for 12 weeks.
The primary objective is to assess the effect of PLH-2301 on physical function compared with placebo.

Start Date08 May 2026

Sponsor / Collaborator

Pluto, Inc.

[+1]

100 Clinical Results associated with PLH-2301

Login to view more data

100 Translational Medicine associated with PLH-2301

Login to view more data

100 Patents (Medical) associated with PLH-2301

Login to view more data

100 Deals associated with PLH-2301

Login to view more data